Structure-Activity and Structure-Property Relationship and Exploratory in vivo Evaluation of the Nan

来源 :2015年全国药物化学学术会议暨第五届中英药物化学学术会议 | 被引量 : 0次 | 上传用户:xueyingnn
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Directly disrupting the Keap1-Nrf2 protein-protein interaction(PPI)has been proven an effective way to activate Nrf2.On the basis of the potent Keap1-Nrf2 PPI inhibitor reported by our group previously,we carried out the preliminary structure-activity and structure-property relationship of the ring systems to improve the drug-like properties.
其他文献
Burkitts lymphoma(BL)is a highly aggressive non-Hodgkins lymphoma,with remarkable cell proliferation and metabolism.The oncogene c-Myc highly expresses in BL and plays a key role in facilitating tumor
A novel series of compounds were designed,synthesized and evaluated as multi-target-directed ligands against AD.2 The optimal compound of this series,18d,exhibited significant antioxidant effects(ORAC
Alzheimers disease(AD)is a multifaceted neurodegenerative disorder characterized by progressive cognitive decline and memory loss.Currently,more than 44 million people worldwide are believed to suffer
共轭亚油酸(conjugated linoleic acid,CLA)是含有共轭双键的一系列十八碳二烯酸的混合物。它具有很好的生物活性,可用于食品、医药、保健品等领域[1-5]。本文以红花油为原料,研究了两种共轭亚油酸乙酯合成方法,并进行了比较。
洛克沙生(Roxarsone,ROX)是广泛使用的畜禽抗菌、促生长有机胂类药物,长期大量使用会严重造成环境中砷污染,因此开发对洛克沙生具有特异性识别和吸附的有机功能材料具有重要意义[1-2]。
Studies regarding the relationship between AA metabolic process and carcinogenesis revealed the novel molecular target for cancer treatment [1].It has been reported that COX-2 and 5-LOX are upregulate
水飞蓟素是一种重要的医药原料,主要成分为水飞蓟宁,水飞蓟亭,水飞蓟宾A,水飞蓟宾B,异水飞蓟宾A和异水飞蓟宾B六种黄酮木脂素类化合物的混合物[1-5]。本文以新疆乌苏产水飞蓟为原料,考察了不同溶剂乙醇、乙酸乙酯、丙酮对水飞蓟素提取效率的影响。
Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation(AF),the most common arrhythmia that threatens human.Herein,by modifying the hit compound
一氧化氮(NO)作为信使物质或效应分子在心血管、免疫等系统发挥重要的生理作用[1]。由于NO 的多种生物活性以及"双刃剑"的作用,利用高浓度的NO来实现抗肿瘤则需要选择性和靶向性地将NO定点输送到肿瘤细胞中,尽可能的减少NO 在非靶部位的释放而带来的副作用。
2005年,拥有自主知识产权的丁苯酞软胶囊被国家药监局批准上市,成为国际上首个作用于急性缺血性脑卒中多个病理环节的创新药物。丁苯酞能重建脑缺血区微循环,显著缩小脑梗塞面积,并能保护线粒体功能,改善脑代谢。